-+ 0.00%
-+ 0.00%
-+ 0.00%

TD Cowen Maintains Hold on Myriad Genetics, Lowers Price Target to $4

Benzinga·07/31/2026 16:59:11
Listen to the news
TD Cowen analyst Kyle Boucher maintains Myriad Genetics (NASDAQ:MYGN) with a Hold and lowers the price target from $6 to $4.